Study Finds Yearly Cost of Patent Thickets on Five Top-Selling Brand Name Drugs Ranges from $1.8 to $7.6 Billion In case you missed it, a new report from The Coalition for Affordable Prescription Drugs (CAPD) and conducted by Matrix Global
In case you missed it, the Pharmaceutical Care Management Association (PCMA) released a new Rx Research Corner blog, by Vice President of Research Amanda Frost, that quantifies what a world without pharmacy benefit companies would look like for employers and
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today is announcing the additions of Amanda Frost as Assistant Vice President, Research and Timothy Dube as Assistant Vice President, Regulatory Affairs. PCMA is also announcing new roles for Kristin Bass and
(Washington, D.C.) — New data from the National Council for Prescription Drug Programs (NCPDP) database, highlighted today by the Pharmaceutical Care Management Association (PCMA), shows that the independent retail pharmacy market in the United States is stable. Over the last 10 years,
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. PLEASE, JUST THE FACTS ON PHARMACY COUNTS… When it comes to
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on the New York Senate Investigations and Government Operations Committee’s report on pharmacy benefit managers (PBMs). “This report attempts to undermine the only industry that is reducing prescription drug
Lawmakers: Increase Competition In The Prescription Drug Market – Don’t Constrain It. S. 127, the “Pharmacy Benefit Manager Transparency Act of 2023” fundamentally misconstrues the role of pharmacy benefit companies, who are working every day to secure savings, enable better
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) is announcing the additions of Angela Banks as Vice President, Policy; Jonathan Buxton as Director, State Affairs; and Peter Fjelstad as Director, State Regulatory and Legal Affairs, as well as new
New Research Paper Demonstrates Declining Biosimilars Prices and Increasing Health Plan Coverage (Washington, D.C.) — Pharmacy benefit managers, PBMs, support the proliferation and use of biosimilars. A robust biosimilar market will increase competition for biologic drugs and provide added choice
With the recent launch of a new adalimumab biosimilar, the U.S. biosimilar market is becoming more competitive, increasing the potential for these more affordable options to play a critical role in helping to lower prescription drug costs for Americans. As biosimilar competition
©2024 PCMA. All Rights Reserved.
